Project Grant R43NS139719
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $500K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Swissvale, PA 15218, USA
Similar Awards
- Renerva LLC, a for-profit manufacturer, is developing peripheral nerve matrix (PNM) technologies to facilitate functional recovery in animal models of direct muscle neurotization (DMN) through a $494,955 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The two-year project aims to 1) optimize the formulation of a clinical-grade PNM product to provide...
- This $1,188,230 federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research by the University of Utah to investigate the pathophysiology of peripheral nerve regeneration and neuroma formation. The key objectives are to evaluate the cellular and molecular mechanisms driving failed nerve regeneration and the development...
- This $999,998 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports the development of Renerva LLC's Peripheral Nerve Matrix (PNM) technology. PNM is a tissue-based hydrogel derived from porcine nerve that aims to improve functional outcomes for patients with challenging peripheral nerve gap injuries. The Phase I project will optimize the PNM...
- This $499,863 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the use of a new class of small molecules called Parmodulins for the treatment of neuropathic pain. The grant recipient, Function Therapeutics Inc., will synthesize and test various Parmodulins for their ability to modulate the protease-activated receptor 1 (PAR1) signaling in a way that reduces inflammation...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $296,151 to Insoma Bio, Inc. to investigate the use of their proprietary Fractomer biomaterial to improve outcomes after peripheral nerve repair. The project aims to demonstrate that Fractomer, an injectable polypeptide scaffold, can provide the necessary mechanical support and...
- The National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant, awarded Clemson University a $310,834 Project Grant for the development of a noninvasive nanoparticle-based therapy to deliver drugs to the peripheral nervous system. The project aims to design and implement a nerve-targeting polymersome platform that can penetrate the blood-nerve barrier and promote functional recovery...
- The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, awarded a $3,242,520 Cooperative Agreement to the University of Pittsburgh on September 1, 2025 to develop a fully implanted spinal cord stimulation (SCS) system to restore sensation and relieve phantom limb pain (PLP) in people with lower-limb amputation. The project aims to quantify the safety and feasibility of the SCS system and explore changes in brain representations associated...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $400,000 Project Grant to Navega Therapeutics, Inc., a San Diego-based biotechnology company, under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support Navega's research and development efforts to advance novel epigenetic gene therapies targeting the voltage-gated sodium channel NAV1.7 for the treatment of chronic pain. This innovative approach aims to transiently repress NAV1.7...
- This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
- The National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $2,714,830 Project Grant to The Johns Hopkins University to investigate the function of medium to large diameter sensory neurons in paclitaxel-induced peripheral neuropathy (PIPN). The project, scheduled to run from August 2025 to July 2030, will utilize a novel in vivo imaging technology to monitor the activity of dorsal root ganglion neurons and...